mouse rna epi-transcriptomic microarray (8 × 60k) Search Results


mouse mrna & lncrna epitranscriptomic microarray  (Arraystar inc)
90
Arraystar inc mouse mrna & lncrna epitranscriptomic microarray
Mouse Mrna & Lncrna Epitranscriptomic Microarray, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse mrna & lncrna epitranscriptomic microarray/product/Arraystar inc
Average 90 stars, based on 1 article reviews
mouse mrna & lncrna epitranscriptomic microarray - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
mouse m6amrna&lncrna epitranscriptomic microarray  (Arraystar inc)
90
Arraystar inc mouse m6amrna&lncrna epitranscriptomic microarray
Mouse M6amrna&Lncrna Epitranscriptomic Microarray, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse m6amrna&lncrna epitranscriptomic microarray/product/Arraystar inc
Average 90 stars, based on 1 article reviews
mouse m6amrna&lncrna epitranscriptomic microarray - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
m6a epitranscriptomic microarray test  (Arraystar inc)
90
Arraystar inc m6a epitranscriptomic microarray test
M6a Epitranscriptomic Microarray Test, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/m6a epitranscriptomic microarray test/product/Arraystar inc
Average 90 stars, based on 1 article reviews
m6a epitranscriptomic microarray test - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
rat epitranscriptomic microarray  (Arraystar inc)
90
Arraystar inc rat epitranscriptomic microarray
m6A sequencing and microarray data in GEO related to CVD.
Rat Epitranscriptomic Microarray, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat epitranscriptomic microarray/product/Arraystar inc
Average 90 stars, based on 1 article reviews
rat epitranscriptomic microarray - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
mirneasy mini-kit  (Arraystar inc)
90
Arraystar inc mirneasy mini-kit
m6A sequencing and microarray data in GEO related to CVD.
Mirneasy Mini Kit, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mirneasy mini-kit/product/Arraystar inc
Average 90 stars, based on 1 article reviews
mirneasy mini-kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
super rna labeling kit  (Arraystar inc)
90
Arraystar inc super rna labeling kit
m6A sequencing and microarray data in GEO related to CVD.
Super Rna Labeling Kit, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/super rna labeling kit/product/Arraystar inc
Average 90 stars, based on 1 article reviews
super rna labeling kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
psat1  (Proteintech)
96
Proteintech psat1
The molecular and clinical characteristics of LP subtype breast cancer. (A) Stacked bar plot showing the deconvolution result of breast tumors from the METABRIC cohort. Colors of the bars denote three cell lineages as shown in the legend. The y axis stands for the proportion of each cell lineage in a given bulk tumor sample. Within the x axis, each column represents one tumor case. The annotation bar above denotes the molecular subtypes of bulk tumors that are defined by the dominant cell lineage within each tumor, where yellow represents the mixture of multiple cell lineages. (B) Kaplan-Meier plot showing worse clinical outcome in LP subtype patients within the METABRIC cohort. P value is calculated using the log-rank test. (C) Spearman correlation between LP score and diverse mutational signatures. Correlations with P < 0.05 are marked with an asterisk. (D) Violin plot comparing the HRD score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (E) Violin plot comparing the expression level of LP score of breast tumors with different responses to NAC treatment. Unpaired two-sided Wilcoxon test. (F) Violin plot comparing the expression level of LP score of breast tumors with different responses to PARP inhibitor treatment in the I-SPY2 cohort. Unpaired two-sided Wilcoxon test. (G) Bubble heatmap showing up-regulated pathways enriched in breast tumors with high LP proportion via GSEA. Dot size indicates the normalized enrichment score (NES), colored based on the adjusted P value. (H) Violin plot comparing the T cell exhausted signature score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (I) Violin plot comparing the expression level of LP score of breast cancer patients with different responses to anti-PD1 treatment. Unpaired two-sided Wilcoxon test. (J) Immunohistochemistry of breast tissue microarray for <t>PSAT1,</t> ER and CK14. (K) LP subtype of breast cancer patients with PSAT1 high /ER low /CK14 low were associated with poor DFS. P value is calculated using the log-rank test.
Psat1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/psat1/product/Proteintech
Average 96 stars, based on 1 article reviews
psat1 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
m-epi-500-ca  (Thermo Fisher)
90
Thermo Fisher m-epi-500-ca
The molecular and clinical characteristics of LP subtype breast cancer. (A) Stacked bar plot showing the deconvolution result of breast tumors from the METABRIC cohort. Colors of the bars denote three cell lineages as shown in the legend. The y axis stands for the proportion of each cell lineage in a given bulk tumor sample. Within the x axis, each column represents one tumor case. The annotation bar above denotes the molecular subtypes of bulk tumors that are defined by the dominant cell lineage within each tumor, where yellow represents the mixture of multiple cell lineages. (B) Kaplan-Meier plot showing worse clinical outcome in LP subtype patients within the METABRIC cohort. P value is calculated using the log-rank test. (C) Spearman correlation between LP score and diverse mutational signatures. Correlations with P < 0.05 are marked with an asterisk. (D) Violin plot comparing the HRD score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (E) Violin plot comparing the expression level of LP score of breast tumors with different responses to NAC treatment. Unpaired two-sided Wilcoxon test. (F) Violin plot comparing the expression level of LP score of breast tumors with different responses to PARP inhibitor treatment in the I-SPY2 cohort. Unpaired two-sided Wilcoxon test. (G) Bubble heatmap showing up-regulated pathways enriched in breast tumors with high LP proportion via GSEA. Dot size indicates the normalized enrichment score (NES), colored based on the adjusted P value. (H) Violin plot comparing the T cell exhausted signature score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (I) Violin plot comparing the expression level of LP score of breast cancer patients with different responses to anti-PD1 treatment. Unpaired two-sided Wilcoxon test. (J) Immunohistochemistry of breast tissue microarray for <t>PSAT1,</t> ER and CK14. (K) LP subtype of breast cancer patients with PSAT1 high /ER low /CK14 low were associated with poor DFS. P value is calculated using the log-rank test.
M Epi 500 Ca, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/m-epi-500-ca/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
m-epi-500-ca - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
humanmethylation27  (Illumina Inc)
90
Illumina Inc humanmethylation27
The molecular and clinical characteristics of LP subtype breast cancer. (A) Stacked bar plot showing the deconvolution result of breast tumors from the METABRIC cohort. Colors of the bars denote three cell lineages as shown in the legend. The y axis stands for the proportion of each cell lineage in a given bulk tumor sample. Within the x axis, each column represents one tumor case. The annotation bar above denotes the molecular subtypes of bulk tumors that are defined by the dominant cell lineage within each tumor, where yellow represents the mixture of multiple cell lineages. (B) Kaplan-Meier plot showing worse clinical outcome in LP subtype patients within the METABRIC cohort. P value is calculated using the log-rank test. (C) Spearman correlation between LP score and diverse mutational signatures. Correlations with P < 0.05 are marked with an asterisk. (D) Violin plot comparing the HRD score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (E) Violin plot comparing the expression level of LP score of breast tumors with different responses to NAC treatment. Unpaired two-sided Wilcoxon test. (F) Violin plot comparing the expression level of LP score of breast tumors with different responses to PARP inhibitor treatment in the I-SPY2 cohort. Unpaired two-sided Wilcoxon test. (G) Bubble heatmap showing up-regulated pathways enriched in breast tumors with high LP proportion via GSEA. Dot size indicates the normalized enrichment score (NES), colored based on the adjusted P value. (H) Violin plot comparing the T cell exhausted signature score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (I) Violin plot comparing the expression level of LP score of breast cancer patients with different responses to anti-PD1 treatment. Unpaired two-sided Wilcoxon test. (J) Immunohistochemistry of breast tissue microarray for <t>PSAT1,</t> ER and CK14. (K) LP subtype of breast cancer patients with PSAT1 high /ER low /CK14 low were associated with poor DFS. P value is calculated using the log-rank test.
Humanmethylation27, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/humanmethylation27/product/Illumina Inc
Average 90 stars, based on 1 article reviews
humanmethylation27 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cell counting kit-8  (Dojindo Labs)
90
Dojindo Labs cell counting kit-8
The molecular and clinical characteristics of LP subtype breast cancer. (A) Stacked bar plot showing the deconvolution result of breast tumors from the METABRIC cohort. Colors of the bars denote three cell lineages as shown in the legend. The y axis stands for the proportion of each cell lineage in a given bulk tumor sample. Within the x axis, each column represents one tumor case. The annotation bar above denotes the molecular subtypes of bulk tumors that are defined by the dominant cell lineage within each tumor, where yellow represents the mixture of multiple cell lineages. (B) Kaplan-Meier plot showing worse clinical outcome in LP subtype patients within the METABRIC cohort. P value is calculated using the log-rank test. (C) Spearman correlation between LP score and diverse mutational signatures. Correlations with P < 0.05 are marked with an asterisk. (D) Violin plot comparing the HRD score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (E) Violin plot comparing the expression level of LP score of breast tumors with different responses to NAC treatment. Unpaired two-sided Wilcoxon test. (F) Violin plot comparing the expression level of LP score of breast tumors with different responses to PARP inhibitor treatment in the I-SPY2 cohort. Unpaired two-sided Wilcoxon test. (G) Bubble heatmap showing up-regulated pathways enriched in breast tumors with high LP proportion via GSEA. Dot size indicates the normalized enrichment score (NES), colored based on the adjusted P value. (H) Violin plot comparing the T cell exhausted signature score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (I) Violin plot comparing the expression level of LP score of breast cancer patients with different responses to anti-PD1 treatment. Unpaired two-sided Wilcoxon test. (J) Immunohistochemistry of breast tissue microarray for <t>PSAT1,</t> ER and CK14. (K) LP subtype of breast cancer patients with PSAT1 high /ER low /CK14 low were associated with poor DFS. P value is calculated using the log-rank test.
Cell Counting Kit 8, supplied by Dojindo Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell counting kit-8/product/Dojindo Labs
Average 90 stars, based on 1 article reviews
cell counting kit-8 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
rneasy micro  (Qiagen)
90
Qiagen rneasy micro
The molecular and clinical characteristics of LP subtype breast cancer. (A) Stacked bar plot showing the deconvolution result of breast tumors from the METABRIC cohort. Colors of the bars denote three cell lineages as shown in the legend. The y axis stands for the proportion of each cell lineage in a given bulk tumor sample. Within the x axis, each column represents one tumor case. The annotation bar above denotes the molecular subtypes of bulk tumors that are defined by the dominant cell lineage within each tumor, where yellow represents the mixture of multiple cell lineages. (B) Kaplan-Meier plot showing worse clinical outcome in LP subtype patients within the METABRIC cohort. P value is calculated using the log-rank test. (C) Spearman correlation between LP score and diverse mutational signatures. Correlations with P < 0.05 are marked with an asterisk. (D) Violin plot comparing the HRD score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (E) Violin plot comparing the expression level of LP score of breast tumors with different responses to NAC treatment. Unpaired two-sided Wilcoxon test. (F) Violin plot comparing the expression level of LP score of breast tumors with different responses to PARP inhibitor treatment in the I-SPY2 cohort. Unpaired two-sided Wilcoxon test. (G) Bubble heatmap showing up-regulated pathways enriched in breast tumors with high LP proportion via GSEA. Dot size indicates the normalized enrichment score (NES), colored based on the adjusted P value. (H) Violin plot comparing the T cell exhausted signature score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (I) Violin plot comparing the expression level of LP score of breast cancer patients with different responses to anti-PD1 treatment. Unpaired two-sided Wilcoxon test. (J) Immunohistochemistry of breast tissue microarray for <t>PSAT1,</t> ER and CK14. (K) LP subtype of breast cancer patients with PSAT1 high /ER low /CK14 low were associated with poor DFS. P value is calculated using the log-rank test.
Rneasy Micro, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rneasy micro/product/Qiagen
Average 90 stars, based on 1 article reviews
rneasy micro - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
chir99021  (Millipore)
90
Millipore chir99021
The molecular and clinical characteristics of LP subtype breast cancer. (A) Stacked bar plot showing the deconvolution result of breast tumors from the METABRIC cohort. Colors of the bars denote three cell lineages as shown in the legend. The y axis stands for the proportion of each cell lineage in a given bulk tumor sample. Within the x axis, each column represents one tumor case. The annotation bar above denotes the molecular subtypes of bulk tumors that are defined by the dominant cell lineage within each tumor, where yellow represents the mixture of multiple cell lineages. (B) Kaplan-Meier plot showing worse clinical outcome in LP subtype patients within the METABRIC cohort. P value is calculated using the log-rank test. (C) Spearman correlation between LP score and diverse mutational signatures. Correlations with P < 0.05 are marked with an asterisk. (D) Violin plot comparing the HRD score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (E) Violin plot comparing the expression level of LP score of breast tumors with different responses to NAC treatment. Unpaired two-sided Wilcoxon test. (F) Violin plot comparing the expression level of LP score of breast tumors with different responses to PARP inhibitor treatment in the I-SPY2 cohort. Unpaired two-sided Wilcoxon test. (G) Bubble heatmap showing up-regulated pathways enriched in breast tumors with high LP proportion via GSEA. Dot size indicates the normalized enrichment score (NES), colored based on the adjusted P value. (H) Violin plot comparing the T cell exhausted signature score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (I) Violin plot comparing the expression level of LP score of breast cancer patients with different responses to anti-PD1 treatment. Unpaired two-sided Wilcoxon test. (J) Immunohistochemistry of breast tissue microarray for <t>PSAT1,</t> ER and CK14. (K) LP subtype of breast cancer patients with PSAT1 high /ER low /CK14 low were associated with poor DFS. P value is calculated using the log-rank test.
Chir99021, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chir99021/product/Millipore
Average 90 stars, based on 1 article reviews
chir99021 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


m6A sequencing and microarray data in GEO related to CVD.

Journal: Frontiers in Genetics

Article Title: m6A Methylation in Cardiovascular Diseases: From Mechanisms to Therapeutic Potential

doi: 10.3389/fgene.2022.908976

Figure Lengend Snippet: m6A sequencing and microarray data in GEO related to CVD.

Article Snippet: GSE159309 , GPL25916 Arraystar Rat Epitranscriptomic microarray , m6A mRNA epitranscriptomic microarray , China , 18 Aug 2021 , Rattus norvegicus , m6A-modified transcripts between a control group and an lipopolysaccharide (LPS)-induced septic cardiomyopathy group , Septic cardiomyopathy.

Techniques: Sequencing, Microarray, Next-Generation Sequencing, Methylation, Control, Dissection

The molecular and clinical characteristics of LP subtype breast cancer. (A) Stacked bar plot showing the deconvolution result of breast tumors from the METABRIC cohort. Colors of the bars denote three cell lineages as shown in the legend. The y axis stands for the proportion of each cell lineage in a given bulk tumor sample. Within the x axis, each column represents one tumor case. The annotation bar above denotes the molecular subtypes of bulk tumors that are defined by the dominant cell lineage within each tumor, where yellow represents the mixture of multiple cell lineages. (B) Kaplan-Meier plot showing worse clinical outcome in LP subtype patients within the METABRIC cohort. P value is calculated using the log-rank test. (C) Spearman correlation between LP score and diverse mutational signatures. Correlations with P < 0.05 are marked with an asterisk. (D) Violin plot comparing the HRD score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (E) Violin plot comparing the expression level of LP score of breast tumors with different responses to NAC treatment. Unpaired two-sided Wilcoxon test. (F) Violin plot comparing the expression level of LP score of breast tumors with different responses to PARP inhibitor treatment in the I-SPY2 cohort. Unpaired two-sided Wilcoxon test. (G) Bubble heatmap showing up-regulated pathways enriched in breast tumors with high LP proportion via GSEA. Dot size indicates the normalized enrichment score (NES), colored based on the adjusted P value. (H) Violin plot comparing the T cell exhausted signature score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (I) Violin plot comparing the expression level of LP score of breast cancer patients with different responses to anti-PD1 treatment. Unpaired two-sided Wilcoxon test. (J) Immunohistochemistry of breast tissue microarray for PSAT1, ER and CK14. (K) LP subtype of breast cancer patients with PSAT1 high /ER low /CK14 low were associated with poor DFS. P value is calculated using the log-rank test.

Journal: Theranostics

Article Title: Single-cell analyses reveal evolution mimicry during the specification of breast cancer subtype

doi: 10.7150/thno.96163

Figure Lengend Snippet: The molecular and clinical characteristics of LP subtype breast cancer. (A) Stacked bar plot showing the deconvolution result of breast tumors from the METABRIC cohort. Colors of the bars denote three cell lineages as shown in the legend. The y axis stands for the proportion of each cell lineage in a given bulk tumor sample. Within the x axis, each column represents one tumor case. The annotation bar above denotes the molecular subtypes of bulk tumors that are defined by the dominant cell lineage within each tumor, where yellow represents the mixture of multiple cell lineages. (B) Kaplan-Meier plot showing worse clinical outcome in LP subtype patients within the METABRIC cohort. P value is calculated using the log-rank test. (C) Spearman correlation between LP score and diverse mutational signatures. Correlations with P < 0.05 are marked with an asterisk. (D) Violin plot comparing the HRD score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (E) Violin plot comparing the expression level of LP score of breast tumors with different responses to NAC treatment. Unpaired two-sided Wilcoxon test. (F) Violin plot comparing the expression level of LP score of breast tumors with different responses to PARP inhibitor treatment in the I-SPY2 cohort. Unpaired two-sided Wilcoxon test. (G) Bubble heatmap showing up-regulated pathways enriched in breast tumors with high LP proportion via GSEA. Dot size indicates the normalized enrichment score (NES), colored based on the adjusted P value. (H) Violin plot comparing the T cell exhausted signature score between LP-low and LP-high breast tumors in TCGA. Unpaired two-sided Wilcoxon test. (I) Violin plot comparing the expression level of LP score of breast cancer patients with different responses to anti-PD1 treatment. Unpaired two-sided Wilcoxon test. (J) Immunohistochemistry of breast tissue microarray for PSAT1, ER and CK14. (K) LP subtype of breast cancer patients with PSAT1 high /ER low /CK14 low were associated with poor DFS. P value is calculated using the log-rank test.

Article Snippet: Six series of tissue microarray were used to detect PSAT1 (Proteintech, 10501-1-AP, 1:200), ER (Proteintech, 21244-1-AP, 1:200), CK14 (Servicebio, GB11803, 1:200), CKB (Proteintech, 66714-1-IG, 1:500) and CA4 (Proteintech, 13931-1-AP, 1:200).

Techniques: Expressing, Immunohistochemistry, Microarray